NEW YORK, NY / ACCESSWIRE / March 7, 2022 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit. If you suffered a loss, you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.
First Solar, Inc. (NASDAQ:FSLR)
This lawsuit is on behalf of all persons or entities that purchased or otherwise acquired shares of First Solar common stock between February 22, 2019, and February 20, 2020, inclusive.
Lead Plaintiff Deadline: March 8, 2022
According to the filed complaint, defendants made repeated misrepresentations to investors regarding the development of First Solar's newest "Series 6" solar module, the cost per unit it could achieve with that module, and the impact the changeover to this new product would have on the viability of its other business segments. As a result of defendants' misrepresentations, First Solar common stock traded at artificially inflated prices during the class period.
Learn about your recoverable losses in FSLR: https://www.kleinstocklaw.com/pslra-1/first-solar-inc-loss-submission-form?id=24378&from=1
Fennec Pharmaceuticals Inc. (NASDAQ:FENC)
Class Period: May 28, 2021 - November 26, 2021
Lead Plaintiff Deadline: April 11, 2022
Fennec Pharmaceuticals Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (i) Fennec had not successfully remediated, and overstated its efforts to remediate, issues with the manufacturing facility of its drug product manufacturer for PEDMARK, a new compound developed to reduce the incidence of hearing loss in children undergoing chemotherapy; (ii) as a result, the Food and Drug Administration likely to approve the Resubmitted Pedmark New Drug Application ("NDA"); (iii) accordingly, the regulatory and commercial prospects of the Resubmitted Pedmark NDA were overstated; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.
Learn about your recoverable losses in FENC: https://www.kleinstocklaw.com/pslra-1/fennec-pharmaceuticals-inc-loss-submission-form-2?id=24378&from=1
Acutus Medical, Inc. (NASDAQ:AFIB)
This lawsuit is on behalf of all purchasers of Acutus common stock between May 13, 2021 and November 11, 2021, inclusive.
Lead Plaintiff Deadline: April 18, 2022
During the class period, Acutus Medical, Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (a) a material percentage of the Company's AcQMap imaging and mapping systems under evaluation had been randomly installed at sites with little, if any, consideration given to whether the healthcare providers at the selected locations were likely to adopt, or desire, the Company's products; (b) a material percentage of the AcQMap systems under evaluation had been installed in locations where the Company did not possess the infrastructure necessary to appropriately educate, train, and support medical service providers on the system's operations; (c) as a result of (a) and (b) above, defendants were in the process of designing a strategic plan to terminate and relocate approximately 20% of then-existing AcQMap systems evaluation arrangements; (d) the Company's management discussion and analysis was materially false and misleading and failed to disclose that the termination and relocation of approximately 20% of existing AcQMap systems evaluation arrangements was reasonably likely to have a material adverse effect on the Company's 2021 financial results; and (e) the Company's risk factor discussions were materially false and misleading and made reference to potential risks without disclosing that such risks were then-existing or adequately describing the specific nature of the risks then facing the Company.
Learn about your recoverable losses in AFIB: https://www.kleinstocklaw.com/pslra-1/acutus-medical-inc-loss-submission-form?id=24378&from=1
Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.
J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
[email protected]
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com
SOURCE : The Klein Law Firm